Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02965378 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

43

Enrollment

NETWORK

Sponsor class

Conditions

FGFR1 Gene Amplification
FGFR1 Gene Mutation
FGFR2 Gene Amplification
FGFR2 Gene Mutation
FGFR3 Gene Amplification
FGFR3 Gene Mutation
Recurrent Squamous Cell Lung Carcinoma
Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions

DRUG: Docetaxel
DRUG: FGFR Inhibitor AZD4547
OTHER: Laboratory Biomarker Analysis

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]